Table 2.

PARPi versus placebo: the specific adverse events which only reported in the specific trial

Trail ID	Specific adverse events
PAOLA-1 (Olaparib + bevacizumab)	lymphopeniaa, urinary tract infectiona, musculoskeletal paina, edemaa, stomatitis or pharyngitisa, renal impairment, proteinuriaa, intestinal obstructiona, cystitis, sleep disordera, muscle spasms, rasha, erythema, neck pain, coronary artery diseasea, pyelonephritis, cardiac failurea, acute lymphocytic leukaemia, acute pyelonephritis, erythematous rash, kidney infection, lung cancer, myeloma, pancreatic cancer, pruritic rash, squamous skin cancer, umbilical erythema, balance disorder, pyuria, urosepsis, dysgeusiab
SOLO1 (Olaparib)	upper abdominal pain, dyspepsia, head and neck cancer
PRIMA (Niraparib)	platelet count decreaseda, neutrophil count decreaseda, astheniaa, white blood cell count decreaseda, hot flusha, abdominal distension, blood creatinine increasedb, coughb
VELIA (Veliparib + chemotherapy)	back painb

^aAll GRADE including GRADE >  = 3

^bGRADE >  = 3